Technical Analysis for BHVN - Biohaven Pharmaceutical Holding Company Ltd.

Grade Last Price % Change Price Change
grade B 51.08 4.20% 2.06
BHVN closed up 4.2 percent on Friday, November 15, 2019, on 1.47 times normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Up Up
See historical BHVN trend table...

Date Alert Name Type % Chg
Expansion Breakout Bullish Swing Setup 0.00%
Pocket Pivot Bullish Swing Setup 0.00%
Upper Bollinger Band Walk Strength 0.00%
Multiple of Ten Bullish Other 0.00%
Above Upper BB Strength 0.00%
Overbought Stochastic Strength 0.00%
Upper Bollinger Band Touch Strength 0.00%
Stochastic Sell Signal Bearish 4.20%
BB Squeeze Ended Range Expansion 4.20%
Overbought Stochastic Strength 4.20%

Older signals for BHVN ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Biohaven Pharmaceutical Holding Company Ltd. is a United States-based biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. It has a portfolio of multiple late-stage drug candidates. Its pipeline includes BHV-0223, which is a formulation of a glutamate-modulating agent; BHV-4157, which is a new chemical entity (NCE) that modulates glutamate, and BHV-5000, which is an in-licensed investigational agent of the Company targeting N-Methyl-D-Aspartate (NMDA) receptor antagonism. Its clinical compound, trigriluzole, is indicated for neurodegenerative diseases and cancer indications, among others. Its pipeline also includes BHV-3000 and BHV-3500, which are in-licensed by the Company for a neurologic indication. It focuses on advancing other mechanistic approaches in orphan and neuroscience indications, and is exploring licenses for additional compounds.
Biopharmaceutical Cancer Drugs Chemical Compounds Organic Compounds Neuroscience Neurodegenerative Diseases Riluzole
Is BHVN a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 67.86
52 Week Low 29.17
Average Volume 605,527
200-Day Moving Average 48.1438
50-Day Moving Average 45.3016
20-Day Moving Average 47.1375
10-Day Moving Average 47.909
Average True Range 1.9785
ADX 20.42
+DI 28.6235
-DI 13.3214
Chandelier Exit (Long, 3 ATRs ) 45.5645
Chandelier Exit (Short, 3 ATRs ) 49.6655
Upper Bollinger Band 50.1337
Lower Bollinger Band 44.1413
Percent B (%b) 1.16
BandWidth 12.712596
MACD Line 1.3546
MACD Signal Line 1.0588
MACD Histogram 0.2959
Fundamentals Value
Market Cap 1.83 Billion
Num Shares 35.8 Million
EPS -7.54
Price-to-Earnings (P/E) Ratio -6.77
Price-to-Sales 0.00
Price-to-Book 5.62
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 54.89
Resistance 3 (R3) 54.61 53.05 54.26
Resistance 2 (R2) 53.05 52.08 53.20 54.04
Resistance 1 (R1) 52.07 51.48 52.56 52.35 53.83
Pivot Point 50.51 50.51 50.76 50.66 50.51
Support 1 (S1) 49.53 49.54 50.02 49.81 48.33
Support 2 (S2) 47.97 48.94 48.12 48.12
Support 3 (S3) 46.99 47.97 47.91
Support 4 (S4) 47.27